Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 1996

View Archived Issues

Novel thrombin inhibitors in development at LG Chemical

Heterocyclic tachykinin antagonists revealed by Zeneca

New NK1 antagonists from Ciba-Geigy

Protein tyrosine kinase inhibitors from Warner-Lambert

Anti-TGF-beta MAbs from Celtrix

BMS describes thrombin-activatable plasminogen activator

Japanese researchers describe analgesic tripeptides

Dolastatin 10 derivatives from Teikoku Hormone

Natural antitumor/antifungal agent disclosed by Fujisawa

End-of-the-year European launches for protease inhibitors

U.K. launch for aromatase inhibitor

Bayer launches sustained-release calcium antagonist in U.K.

German launch for bisphosphonate

Thrombolytic agent introduced in Germany

Pharmagenesis forms Chinese joint venture

FDA identifies issues to be addressed for AccuSite approval

U.S. researchers report link between NO formation and AIDS dementia

Geron/P&U collaboration on telomerase inhibitors

Neoprobe files first marketing application with FDA

FDA clears oral monotherapy for PID

Genome Therapeutics and Schering-Plough genomic-based collaboration

Breath-activated inhaler from IVAX licensed to Glaxo Wellcome

Bayer antibacterial cleared for wider use by FDA

Nutropin cleared for marketing

Combination antihypertensive product cleared by FDA

Expanded use of acellular DTP vaccine approved

FDA clears angiotensin II blocker from Ciba

Hyperprolactinemia Rx approved by FDA

Novel anticonvulsant approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...